$TCRT
Alaunos Therapeutics, Inc.

2021 Q4 Form 10-Q Financial Statement

#000095017021003463 Filed on November 08, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q4
Revenue $0.00 $398.0K $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.095M $8.173M $8.803M
YoY Change -76.2% 28.71% 51.25%
% of Gross Profit
Research & Development $8.216M $14.52M $13.97M
YoY Change -41.19% 3.96% 36.69%
% of Gross Profit
Depreciation & Amortization $705.0K $673.0K $420.0K
YoY Change 67.86% -4.94% 133.33%
% of Gross Profit
Operating Expenses $10.31M $22.69M $22.77M
YoY Change -54.72% 11.68% 41.98%
Operating Profit -$22.30M
YoY Change 9.72%
Interest Expense -$738.0K -$444.0K
YoY Change
% of Operating Profit
Other Income/Expense, Net -$5.000K -$437.0K $2.000K
YoY Change -350.0% -7383.33% -99.31%
Pretax Income -$11.79M -$22.73M -$22.77M
YoY Change -48.21% 11.88% 44.58%
Income Tax
% Of Pretax Income
Net Earnings -$11.79M -$22.73M -$22.77M
YoY Change -48.21% 11.9% 44.62%
Net Earnings / Revenue -5711.81%
Basic Earnings Per Share -$0.11
Diluted Earnings Per Share -$54.94K -$106.0K -$106.9K
COMMON SHARES
Basic Shares Outstanding 216.1M 215.6M
Diluted Shares Outstanding 214.5M

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $76.05M $91.73M $115.1M
YoY Change -33.91% -32.29% 44.38%
Cash & Equivalents $76.05M $91.70M $115.1M
Short-Term Investments
Other Short-Term Assets $1.666M $3.319M $10.86M
YoY Change -84.65% -76.58% -51.54%
Inventory
Prepaid Expenses
Receivables $1.111M $1.510M $4.665M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $78.83M $96.55M $130.6M
YoY Change -39.63% -37.74% 23.79%
LONG-TERM ASSETS
Property, Plant & Equipment $10.94M $11.66M $10.23M
YoY Change 6.94% 17.24% 821.71%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $631.0K $2.000K $745.0K
YoY Change -15.3% -99.77% 577.27%
Total Long-Term Assets $16.03M $17.21M $15.76M
YoY Change 1.76% 58.99% 335.01%
TOTAL ASSETS
Total Short-Term Assets $78.83M $96.55M $130.6M
Total Long-Term Assets $16.03M $17.21M $15.76M
Total Assets $94.87M $113.8M $146.3M
YoY Change -35.18% -31.42% 34.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.368M $1.463M $960.0K
YoY Change 42.5% -44.14% 5.96%
Accrued Expenses $6.076M $13.96M $16.59M
YoY Change -63.37% -16.4% 52.95%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $7.868M $12.04M $0.00
YoY Change
Total Short-Term Liabilities $16.04M $28.17M $18.37M
YoY Change -12.67% 45.82% 46.64%
LONG-TERM LIABILITIES
Long-Term Debt $16.25M $12.17M $0.00
YoY Change
Other Long-Term Liabilities $0.00 $4.708M $3.995M
YoY Change -100.0% 184.47% 149.69%
Total Long-Term Liabilities $16.25M $12.17M $0.00
YoY Change 635.59% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.04M $28.17M $18.37M
Total Long-Term Liabilities $16.25M $12.17M $0.00
Total Liabilities $36.81M $45.06M $22.36M
YoY Change 64.6% 114.79% 58.56%
SHAREHOLDERS EQUITY
Retained Earnings -$842.9M -$831.1M -$764.1M
YoY Change 10.31% 11.69%
Common Stock $900.9M $899.8M $888.1M
YoY Change 1.44% 13.98%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $58.06M $68.71M $124.0M
YoY Change
Total Liabilities & Shareholders Equity $94.87M $113.8M $146.3M
YoY Change -35.18% -31.42% 34.12%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q4
OPERATING ACTIVITIES
Net Income -$11.79M -$22.73M -$22.77M
YoY Change -48.21% 11.9% 44.62%
Depreciation, Depletion And Amortization $705.0K $673.0K $420.0K
YoY Change 67.86% -4.94% 133.33%
Cash From Operating Activities -$15.13M -$9.577M -$17.04M
YoY Change -11.21% -76.04% 46.86%
INVESTING ACTIVITIES
Capital Expenditures -$359.0K -$370.0K -$3.766M
YoY Change -90.47% -93.85% -3866.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$359.0K -$370.0K -$3.766M
YoY Change -90.47% -93.85% 3666.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -186.0K 24.93M 400.0K
YoY Change -146.5% -75.5% -86.8%
NET CHANGE
Cash From Operating Activities -15.13M -9.577M -17.04M
Cash From Investing Activities -359.0K -370.0K -3.766M
Cash From Financing Activities -186.0K 24.93M 400.0K
Net Change In Cash -15.67M 14.98M -20.40M
YoY Change -23.19% -73.12% 135.32%
FREE CASH FLOW
Cash From Operating Activities -$15.13M -$9.577M -$17.04M
Capital Expenditures -$359.0K -$370.0K -$3.766M
Free Cash Flow -$14.77M -$9.207M -$13.27M
YoY Change 11.28% -72.89% 13.42%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001107421
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-33038
dei Entity Registrant Name
EntityRegistrantName
ZIOPHARM Oncology, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-1475642
dei Entity Address Address Line1
EntityAddressAddressLine1
One First Avenue
dei Entity Address Address Line2
EntityAddressAddressLine2
Parris Building 34, Navy Yard Plaza
dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02129
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
259-1970
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
ZIOP
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
216145826
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
91725000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
115069000
CY2021Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
1510000
CY2020Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
4665000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3319000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10855000
CY2021Q3 us-gaap Assets Current
AssetsCurrent
96554000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
130589000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11662000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10231000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5179000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4650000
CY2021Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
365000
CY2020Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
130000
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
745000
CY2021Q3 us-gaap Assets
Assets
113762000
CY2020Q4 us-gaap Assets
Assets
146345000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1463000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
960000
CY2021Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
12037000
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
0
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
216000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13963000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
16589000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
215000
CY2021Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
899549000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
887868000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
710000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
819000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
28173000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
18368000
CY2021Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
12174000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4708000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3995000
CY2021Q3 us-gaap Liabilities
Liabilities
45055000
CY2020Q4 us-gaap Liabilities
Liabilities
22363000
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
216145804
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
216145804
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
214591906
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
214591906
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-831058000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-764101000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
68707000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
123982000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
113762000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
146345000
CY2021Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
398000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
398000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14521000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13968000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
41427000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
38725000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8173000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6353000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
25469000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18862000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
22694000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
20321000
us-gaap Operating Expenses
OperatingExpenses
66896000
us-gaap Operating Expenses
OperatingExpenses
57587000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-22296000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-20321000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
412000
us-gaap Net Income Loss
NetIncomeLoss
-57204000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
144918000
ziop Stock Issued During Period Issuance Of Common Stock In Connection With Public Offering
StockIssuedDuringPeriodIssuanceOfCommonStockInConnectionWithPublicOffering
88661000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
13015000
us-gaap Operating Income Loss
OperatingIncomeLoss
-66498000
us-gaap Operating Income Loss
OperatingIncomeLoss
-57587000
CY2021Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-444000
CY2020Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
7000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-444000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
7000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-15000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-29000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-437000
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
6000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-459000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
383000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-22733000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-20315000
us-gaap Net Income Loss
NetIncomeLoss
-66957000
us-gaap Net Income Loss
NetIncomeLoss
-57204000
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.10
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.31
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.27
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
214542465
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
212837367
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
214310349
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
208497410
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
88281000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2371000
CY2021Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0
CY2021Q3 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
788000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-22733000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
68707000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
123982000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9857000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1037000
us-gaap Stock Issued During Period Value Restricted Stock Award Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
0
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
788000
us-gaap Net Income Loss
NetIncomeLoss
-66957000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
68707000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
163414000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1792000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
27000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-20315000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
144918000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
95010000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5393000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
43000
us-gaap Net Income Loss
NetIncomeLoss
-66957000
us-gaap Net Income Loss
NetIncomeLoss
-57204000
us-gaap Depreciation
Depreciation
1892000
us-gaap Depreciation
Depreciation
708000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
148000
us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
9857000
us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
5393000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-3155000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
2098000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-7646000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-8249000
ziop Increase Decrease In Right Of Use Asset
IncreaseDecreaseInRightOfUseAsset
529000
ziop Increase Decrease In Right Of Use Asset
IncreaseDecreaseInRightOfUseAsset
98000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-508000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
636000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
503000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1713000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-3169000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3828000
ziop Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
604000
ziop Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
168000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-46342000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-39977000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2964000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6012000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2964000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6012000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
25000000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
75000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1037000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
43000
us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
0
us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
88661000
ziop Net Proceeds From At The Market Stock Offering
NetProceedsFromAtTheMarketStockOffering
0
ziop Net Proceeds From At The Market Stock Offering
NetProceedsFromAtTheMarketStockOffering
13015000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
25962000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
101719000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-23344000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
55730000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
115069000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
79741000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
91725000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
135471000
us-gaap Interest Paid Net
InterestPaidNet
136000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
348000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1163000
ziop Issuance Costs In Accounts Payable And Accrued Expenses
IssuanceCostsInAccountsPayableAndAccruedExpenses
184000
ziop Warrants Issued In Term Loan
WarrantsIssuedInTermLoan
788000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
91700000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-831100000
CY2020Q4 ziop Minimum Royalties Amount Payable
MinimumRoyaltiesAmountPayable
100000
CY2020Q4 ziop Expected Cash Payment Payable
ExpectedCashPaymentPayable
1500000
CY2021Q2 us-gaap Land Subject To Ground Leases
LandSubjectToGroundLeases
9800
CY2021Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
24211000
CY2021Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
12037000
CY2021Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
12174000
CY2021Q3 us-gaap Debt Instrument Basis Spread On Variable Rate1
DebtInstrumentBasisSpreadOnVariableRate1
0.045
ziop Interest Expense Amortized Date
InterestExpenseAmortizedDate
2023-03-01
CY2021Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
400000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
35386620
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
30997640
CY2021Q3 ziop Payment For Annual License Fees
PaymentForAnnualLicenseFees
0
CY2017 ziop License Agreement Commencement Date
LicenseAgreementCommencementDate
2015-05
CY2019Q1 us-gaap Land Subject To Ground Leases
LandSubjectToGroundLeases
1038
CY2019Q1 ziop Lessee Operating Lease Monthly Average Rental Payment
LesseeOperatingLeaseMonthlyAverageRentalPayment
2000
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
352000
CY2020Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
267000
us-gaap Operating Lease Cost
OperatingLeaseCost
1113000
us-gaap Operating Lease Cost
OperatingLeaseCost
768000
CY2021Q3 us-gaap Lease Cost
LeaseCost
352000
CY2020Q3 us-gaap Lease Cost
LeaseCost
267000
us-gaap Lease Cost
LeaseCost
1113000
us-gaap Lease Cost
LeaseCost
768000
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y8M15D
CY2020Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y11M26D
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y8M15D
CY2020Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y11M26D
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0800
CY2020Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0800
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0800
CY2020Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0800
CY2020Q2 ziop Lessee Operating Lease Monthly Average Rental Payment
LesseeOperatingLeaseMonthlyAverageRentalPayment
10000
CY2021Q3 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
0
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
5000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
273000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1102000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1132000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1166000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1201000
CY2021Q3 ziop Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
1873000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
6747000
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1329000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
5418000
CY2021Q3 us-gaap Share Based Compensation
ShareBasedCompensation
2371000
CY2020Q3 us-gaap Share Based Compensation
ShareBasedCompensation
1792000
us-gaap Share Based Compensation
ShareBasedCompensation
9857000
us-gaap Share Based Compensation
ShareBasedCompensation
5393000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
2755000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
7150438
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.08
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.91
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
203178
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1252178
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.96
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.45
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
216700
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
751371
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
10417
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
347267
ziop Additional Stock Compensation Expenses
AdditionalStockCompensationExpenses
2000.0
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0089
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0096
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0036
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0039
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0050
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0115
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0036
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0168
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7253
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.7284
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7359
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.7418
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7253
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.7480
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7111
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.7418
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6840719
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.81
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
7150438
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.97
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
363109
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.86
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
2555154
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.54
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11072894
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.36
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y3M25D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
473000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
5743820
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.08
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y2M26D
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3596315
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.17
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y10M24D
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
598000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2224159
CY2021Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
2400
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y2M8D
CY2019Q3 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
52500000
us-gaap Severance Costs1
SeveranceCosts1
3537000
us-gaap Postemployment Benefits Period Expense
PostemploymentBenefitsPeriodExpense
3500000

Files In Submission

Name View Source Status
0000950170-21-003463-index-headers.html Edgar Link pending
0000950170-21-003463-index.html Edgar Link pending
0000950170-21-003463.txt Edgar Link pending
0000950170-21-003463-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ziop-20210930.htm Edgar Link pending
ziop-20210930.xsd Edgar Link pending
ziop-20210930_cal.xml Edgar Link unprocessable
ziop-20210930_def.xml Edgar Link unprocessable
ziop-20210930_htm.xml Edgar Link completed
ziop-20210930_lab.xml Edgar Link unprocessable
ziop-20210930_pre.xml Edgar Link unprocessable
ziop-ex10_1.htm Edgar Link pending
ziop-ex31_1.htm Edgar Link pending
ziop-ex31_2.htm Edgar Link pending
ziop-ex32_1.htm Edgar Link pending
ziop-ex4_1.htm Edgar Link pending